Significance of combined analysis of PARP1 and EZH2 expression as potentially targetable biomarkers in breast cancer

Conclusion Our findings prove that the combined high PARP1 and EZH2 expression was statistically associated with poor prognosis and survival outcome in early-stage BC, in particular BRCA1-negative and TNBC. Therefore, these results suggest that patients with high PARP1 and EZH2 expression may benefit from combining PARPi and EZH2 inhibitor therapy in BRCA1-negative BCs.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: ORIGINAL ARTICLES Source Type: research